[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
July 21, 2004

FDA Warns Against Breast Milk Drug

JAMA. 2004;292(3):322. doi:10.1001/jama.292.3.322

The Food and Drug Administration (FDA) is cautioning breastfeeding women not to use an unapproved drug, domperidone, which may increase the secretion of prolactin and therefore increase milk production. Several published reports and case studies have linked domperidone to cardiac arrhythmias, cardiac arrest, and sudden death in patients receiving an intravenous form of the drug.

More than 2000 reports of adverse effects from 33 countries have been related to domperidone, and the drug has been withdrawn from marketing in a number of countries. Several nations, including Canada, have approved oral domperidone for gastric disorders, as it increases contractions of the stomach and bowel.

First Page Preview View Large
First page PDF preview
First page PDF preview
×